in this issue
Pharma/Fine Chemicals Roundup – June 6
7:11 AM MDT | June 6, 2012 | By DEEPTI RAMESH
FINE CHEMICAL COMPANIES MAINTAIN GROWTH DESPITE CHALLENGES
Pharmaceutical fine chemical companies and contract manufacturers are seeing a rise in demand for their products and services, and say that the outlook for the industry is positive despite a number of challenges. Companies with operations in all geographic regions expect to see further growth in their businesses and have outlined plans for expansion.
SIEGFRIED ACQUIRES U.S. CONTRACT MANUFACTURING COMPANY
Siegfried (Zofingen, Switzerland), a producer of active pharmaceutical ingredients (APIs), intermediates, and finished drugs, says it has acquired privately-held Alliance Medical Products (AMP; Irvine, CA) for $58 million. AMP is a contract manufacturing organization (CMO) that provides pharmaceutical companies with a complete single source solution from early stage through high volume commercial manufacturing. AMP, which was founded in 2001, provides sterile filling services for medications, an attractive segment of the pharmaceutical custom market, Siegfried says. AMP recorded sales of $20 million in 2011 and the company employs about 100 people. The acquisition is effective immediately and gives Siegfried an entry into the custom market for sterile filling services.
BOEHRINGER INGELHEIM TO INVEST €50 MILLION TO BUILD PILOT PLANT FOR NEW APIS
Boehringer Ingelheim (Ingelheim, Germany) says it will build a new pilot plant facility for the production of newly developed active pharmaceutical ingredients (APIs) at the company’s research and development site at Biberach, Germany. The project will involve an investment of over €50 million ($62 million). Construction of the new facility is scheduled for completion in early 2014.
U.S. LAWMAKERS APPROVE BILL BOLSTERING FDA AUTHORITY ON PHARMA INGREDIENTS
The U.S. Senate and House of Representatives have approved separate bills that would revise FDA’s ability to oversee certain provisions related to pharmaceutical ingredients and includes a generic drug user fee program. The bills will now move to a House and Senate conference to reconcile differences in the two versions.
AMERICAN PACIFIC SHIFTS FOCUS TO PHARMACEUTICALS
American Pacific (Las Vegas) is changing its business plan from rocket-fuel to pharmaceuticals. The company is selling its propulsion business to Moog (New York), a control component and system maker for aircraft and space vehicles, for $46 million. The propulsion business makes liquid-fuel systems for satellites and missile defense, and made about $51 million in sales in the first quarter of 2011, the company says. American Pacific plans to expand its pharmaceutical product line, including active ingredients used as catalysts in medication. Moog says they will use their new acquirement to expand the European sector.
LONZA APPOINTS NEW COO OF LIFE SCIENCE INGREDIENTS BUSINESS
Lonza says Beat In-Albon has joined Lonza, starting June 1, as COO of the life science ingredients sector and has also become a member of the management committee. Beat In-Albon replaces Harry Boot, who will step down from the management committee and concentrate on his activities in Asia, especially in China, Lonza says. Beat In-Albon, prior to accepting his new role, worked with the SGS group (Geneva, Switzerland) from 2006-2012, and for Lonza from 1983-2006, where he was the head of the organic fine & performance chemicals division.
MERCK KGAA AND DR. REDDY’S PARTNER TO DEVELOP AND MANUFACTURE BIOSIMILARS
Merck KGaA says its Merck Serono division will partner with pharmaceutical company Dr. Reddy’s Laboratories (Hyderabad, India) to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.
CODEXIS TAPS ALBEMARLE EXECUTIVE AS NEW CEO
Codexis has named John Nicols its new president and CEO, effective June 13. Nicols has also been named to the company's board of directors. Nicols was named senior vice president of strategic development and catalysts at Albemarle in March, and had served as vice president of the division since 2007, which is one of the company’s largest business units. Nicols was with Albemarle since 1990, and previously served in the company’s flame retardants and fine chemistry units as head of strategic development. Prior to Albemarle, Nicols worked in manufacturing and research development for Hercules.